A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: a phase II study.

Traina, TA, Theodoulou, M, Dugan, U, Feigin, K, Patil, S, Geneus, S, Godfrey, L, Norton, L, Hudis, C (2009) A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: a phase II study. In: UNSPECIFIED.

Item Type: Conference or Workshop Item (Paper)
Subjects: diseases & disorders > cancer > cancer types > breast cancer
CSHL Authors:
Communities: CSHL labs > Wigler lab
SWORD Depositor: CSHL Elements
Depositing User: CSHL Elements
Date: 2009
Date Deposited: 26 May 2022 13:25
Last Modified: 26 May 2022 13:25
Related URLs:
URI: https://repository.cshl.edu/id/eprint/40625

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving